Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 64: Line 64:
 
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] '''FDA approved 6/30/2021'''
 
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] '''FDA approved 6/30/2021'''
 
*[[Atezolizumab (Tecentriq)]]
 
*[[Atezolizumab (Tecentriq)]]
−
*[[Avapritinib (Ayvakit)]] '''FDA approved 1/9/2020'''
+
*[[Avapritinib (Ayvakit)]]
 
*[[Avelumab (Bavencio)]]
 
*[[Avelumab (Bavencio)]]
 
*[[Axicabtagene ciloleucel (Yescarta)]]
 
*[[Axicabtagene ciloleucel (Yescarta)]]
 
*[[Axitinib (Inlyta)]]
 
*[[Axitinib (Inlyta)]]
−
*[[Azacitidine (Onureg)]] '''FDA approved 9/1/2020'''
+
*[[Azacitidine (Onureg)]]
 
*[[Azacitidine (Vidaza)]]
 
*[[Azacitidine (Vidaza)]]
  
Line 78: Line 78:
  
 
*[[Bacillus Calmette-Guérin (BCG)]]
 
*[[Bacillus Calmette-Guérin (BCG)]]
−
*[[Belantamab mafodotin (Blenrep)]] '''FDA approved 8/6/2020'''
+
*[[Belantamab mafodotin (Blenrep)]]
 
*[[Belinostat (Beleodaq)]]
 
*[[Belinostat (Beleodaq)]]
 
*[[Belotecan (Camptobell)]]
 
*[[Belotecan (Camptobell)]]
Line 100: Line 100:
 
*[[Bosutinib (Bosulif)]]
 
*[[Bosutinib (Bosulif)]]
 
*[[Brentuximab vedotin (Adcetris)]]
 
*[[Brentuximab vedotin (Adcetris)]]
−
*[[Brexucabtagene autoleucel (Tecartus)]] '''FDA approved 7/24/2020'''
+
*[[Brexucabtagene autoleucel (Tecartus)]]
 
*[[Brigatinib (Alunbrig)]]
 
*[[Brigatinib (Alunbrig)]]
 
*[[Buserelin (Suprefact)]]
 
*[[Buserelin (Suprefact)]]
Line 117: Line 117:
 
*[[Capecitabine (Xeloda)]]
 
*[[Capecitabine (Xeloda)]]
 
*[[Caplacizumab (Cablivi)]]
 
*[[Caplacizumab (Cablivi)]]
−
*[[Capmatinib (Tabrecta)]] '''FDA approved 5/6/2020'''
+
*[[Capmatinib (Tabrecta)]]
 
*[[Carboplatin (Paraplatin)]]
 
*[[Carboplatin (Paraplatin)]]
 
*[[Carfilzomib (Kyprolis)]]
 
*[[Carfilzomib (Kyprolis)]]
Line 129: Line 129:
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorozotocin (DCNU)]]
 
*[[Chlorozotocin (DCNU)]]
 +
*[[Ciltacabtagene autoleucel (Carvykti)]] '''FDA approved 3/1/2022'''
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cladribine (Leustatin)]]
 
*[[Cladribine (Leustatin)]]
Line 153: Line 154:
 
*[[Dactinomycin (Cosmegen)]]
 
*[[Dactinomycin (Cosmegen)]]
 
*[[Daratumumab (Darzalex)]]
 
*[[Daratumumab (Darzalex)]]
−
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]] '''FDA approved 5/1/2020'''
+
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Dasatinib (Sprycel)]]
 
*[[Dasatinib (Sprycel)]]
Line 159: Line 160:
 
*[[Daunorubicin liposomal (DaunoXome)]]
 
*[[Daunorubicin liposomal (DaunoXome)]]
 
*[[Decitabine (Dacogen)]]
 
*[[Decitabine (Dacogen)]]
−
*[[Decitabine and cedazuridine (Inqovi)]] '''FDA approved 7/7/2020'''
+
*[[Decitabine and cedazuridine (Inqovi)]]
 
*[[Degarelix (Firmagon)]]
 
*[[Degarelix (Firmagon)]]
 
*[[Denileukin diftitox (Ontak)]]
 
*[[Denileukin diftitox (Ontak)]]
Line 265: Line 266:
 
*[[Irinotecan (Camptosar)]]
 
*[[Irinotecan (Camptosar)]]
 
*[[Irinotecan liposome (Onivyde)]]
 
*[[Irinotecan liposome (Onivyde)]]
−
*[[Isatuximab (Sarclisa)]] '''FDA approved 3/2/2020'''
+
*[[Isatuximab (Sarclisa)]]
 
*[[Isotretinoin (Accutane)]]
 
*[[Isotretinoin (Accutane)]]
 
*[[Ivosidenib (Tibsovo)]]
 
*[[Ivosidenib (Tibsovo)]]
Line 297: Line 298:
 
*[[Loncastuximab tesirine (Zynlonta)]] '''FDA approved 4/23/2021'''
 
*[[Loncastuximab tesirine (Zynlonta)]] '''FDA approved 4/23/2021'''
 
*[[Lorlatinib (Lorbrena)]]
 
*[[Lorlatinib (Lorbrena)]]
−
*[[Lurbinectedin (Zepzelca)]] '''FDA approved 6/15/2020'''
+
*[[Lurbinectedin (Zepzelca)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
  
Line 305: Line 306:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
−
*[[Margetuximab (Margenza)]] '''FDA approved on 12/16/2020'''
+
*[[Margetuximab (Margenza)]]
 
*[[Mechlorethamine (Mustargen)]]
 
*[[Mechlorethamine (Mustargen)]]
 
*[[Medroxyprogesterone (MPA)]]
 
*[[Medroxyprogesterone (MPA)]]
Line 318: Line 319:
 
*[[Midostaurin (Rydapt)]]
 
*[[Midostaurin (Rydapt)]]
 
*[[Mifamurtide (Mepact)]]
 
*[[Mifamurtide (Mepact)]]
−
*[[Mitomycin (Jelmyto)]] '''FDA approved on 4/15/2020'''
+
*[[Mitomycin (Jelmyto)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitotane (Lysodren)]]
 
*[[Mitotane (Lysodren)]]
Line 332: Line 333:
 
|}
 
|}
  
−
*[[Naxitamab (Danyelza)]] '''FDA approved 11/24/2020'''
+
*[[Naxitamab (Danyelza)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Nedaplatin (Aqupla)]]
 
*[[Nedaplatin (Aqupla)]]
Line 384: Line 385:
 
*[[Pembrolizumab (Keytruda)]]
 
*[[Pembrolizumab (Keytruda)]]
 
*[[Pemetrexed (Alimta)]]
 
*[[Pemetrexed (Alimta)]]
−
*[[Pemigatinib (Pemazyre)]] '''FDA approved 4/17/2020'''
+
*[[Pemigatinib (Pemazyre)]]
 
*[[Pentostatin (Nipent)]]
 
*[[Pentostatin (Nipent)]]
 
*[[Pertuzumab (Perjeta)]]
 
*[[Pertuzumab (Perjeta)]]
Line 397: Line 398:
 
*[[Porfimer (Photofrin)]]
 
*[[Porfimer (Photofrin)]]
 
*[[Pralatrexate (Folotyn)]]
 
*[[Pralatrexate (Folotyn)]]
−
*[[Pralsetinib (Gavreto)]] '''FDA approved 9/4/2020'''
+
*[[Pralsetinib (Gavreto)]]
 
*[[Prednisone (Sterapred)]]
 
*[[Prednisone (Sterapred)]]
 
*[[Prednisolone (Millipred)]]
 
*[[Prednisolone (Millipred)]]
Line 416: Line 417:
 
*[[Realgar-Indigo naturalis formulation]]
 
*[[Realgar-Indigo naturalis formulation]]
 
*[[Regorafenib (Stivarga)]]
 
*[[Regorafenib (Stivarga)]]
−
*[[Relugolix (Orgovyx)]] '''FDA approved 12/18/2020'''
+
*[[Relugolix (Orgovyx)]]
 
*[[Ribociclib (Kisqali)]]
 
*[[Ribociclib (Kisqali)]]
−
*[[Ripretinib (Qinlock)]] '''FDA approved 5/15/2020'''
+
*[[Ripretinib (Qinlock)]]
 
*[[Rituximab (Rituxan)]]
 
*[[Rituximab (Rituxan)]]
 
**[[Rituximab-abbs (Truxima)]]
 
**[[Rituximab-abbs (Truxima)]]
Line 438: Line 439:
 
|}
 
|}
  
−
*[[Sacituzumab govitecan (Trodelvy)]] '''FDA approved 4/22/2020'''
+
*[[Sacituzumab govitecan (Trodelvy)]]
 
*[[Samarium-153 (Quadramet)]]
 
*[[Samarium-153 (Quadramet)]]
 
*[[Selinexor (Xpovio)]]
 
*[[Selinexor (Xpovio)]]
−
*[[Selpercatinib (Retevmo)]] '''FDA approved 5/8/2020'''
+
*[[Selpercatinib (Retevmo)]]
−
*[[Selumetinib (Koselugo)]] '''FDA approved 4/10/2020'''
+
*[[Selumetinib (Koselugo)]]
 
*[[Semustine (MeCCNU)]]
 
*[[Semustine (MeCCNU)]]
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sipuleucel-T (Provenge)]]
Line 460: Line 461:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
−
*[[Tafasitamab (Monjuvi)]] '''FDA approved 7/31/2020'''
+
*[[Tafasitamab (Monjuvi)]]
 
*[[Tagraxofusp (Elzonris)]]
 
*[[Tagraxofusp (Elzonris)]]
 
*[[Talazoparib (Talzenna)]]
 
*[[Talazoparib (Talzenna)]]
Line 466: Line 467:
 
*[[Tamoxifen (Nolvadex)]]
 
*[[Tamoxifen (Nolvadex)]]
 
*[[Tasonermin (Beromun)]]
 
*[[Tasonermin (Beromun)]]
−
*[[Tazemetostat (Tazverik)]] '''FDA approved 1/23/2020'''
+
*[[Tazemetostat (Tazverik)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
Line 499: Line 500:
 
*[[Trimetrexate (Neutrexin)]]
 
*[[Trimetrexate (Neutrexin)]]
 
*[[Triptorelin (Trelstar LA)]]
 
*[[Triptorelin (Trelstar LA)]]
−
*[[Tucatinib (Tukysa)]] '''FDA approved 4/17/2020'''
+
*[[Tucatinib (Tukysa)]]
  
 
==U==
 
==U==
Line 577: Line 578:
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Cediranib (Recentin)]]
 
*[[Cediranib (Recentin)]]
−
*[[Ciltacabtagene autoleucel (JNJ-68284528)]]
 
 
*[[Cixutumumab (IMC-A12)]]
 
*[[Cixutumumab (IMC-A12)]]
 
*[[Coltuximab ravtansine (CoR, SAR3419)]]
 
*[[Coltuximab ravtansine (CoR, SAR3419)]]

Revision as of 18:27, 1 March 2022

Guidelines

back to top

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Older

Antimicrobials

Growth factors

Approved antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). This includes drugs that are no longer on the market, which are labeled as discontinued. Biosimilars are also indexed here, indented below their parent compound.

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

R

back to top

S

back to top

T

back to top

U

back to top

V

back to top

Z

back to top

Investigational antineoplastics

This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

L

back to top

M

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

back to top

V

back to top

Z

back to top

Supportive and other medications

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Condition

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=55102"